reports
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of February 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and w...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
SCL STEPAN COMPANY
RLI RLI CORP.
NBTB NBT BANCORP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
IPAR INTER PARFUMS INC.
IP INTERNATIONAL PAPER COMPANY
INTC INTEL CORPORATION
GME GAMESTOP CORP. CLASS A
CMC COMMERCIAL METALS COMPANY
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
PAR PAR TECHNOLOGY CORP.
PLBC PLUMAS BANCORP
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
CRVS CORVUS PHARMACEUTICALS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ESQ ESQUIRE FINANCIAL HOLDINGS
ABT ABBOTT LABORATORIES
THM INTERNATIONAL TOWER HILL MINES LTD
NWFL NORWOOD FINANCIAL CORP.
ZIVO ZIVO BIOSCIENCE
ANIX INC.
AMTB ANIXA BIOSCIENCES
CABA AMERANT BANCORP (A)
JYNT CABALETTA BIO
ALLY THE JOINT
ALT GMAC LLC
APG ALTIMMUNE INC
ZNTL API GROUP CORP
AVO ZENTALIS PHARMACEUTICALS
TMC MISSION PRODUCE
IMRX TMC THE METALS CO INC
BST IMMUNEERING CORP
LUCY BLACKROCK SCIENCE AND TECHNOLOGY TRUST
PMCB INNOVATIVE EYEWEAR INC
VANI PHARMACYTE BIOTECH INC
ACRV VIVANI MEDICAL INC
BOF ACRIVON THERAPEUTICS INC
SRBK BRANCHOUT FOOD INC.
WS WI SR BANCORP INC
GDV WORTHINGTON STEEL
GF THE GABELLI DIVIDEND & INCOME TRUST
CVM THE NEW GERMANY FUND
MSTR INC.
BDSX CEL-SCI CORPORATION
MPTI MICROSTRATEGY INCORPORATED
MIGI BIODESIX INC
SQNS M-TRON INDUSTRIES
INC.
MAWSON INFRASTRUCTURE GROUP INC
SEQUANS COMMUNICATIONS
- Jonathan Moreland
SCL STEPAN COMPANY
RLI RLI CORP.
LTC LTC PROPERTIES INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
IPAR INTER PARFUMS INC.
GME GAMESTOP CORP. CLASS A
DAKT DAKTRONICS INC.
CMC COMMERCIAL METALS COMPANY
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
WHF WHITEFIELD
ADC AGREE REALTY CORPORATION
PAR PAR TECHNOLOGY CORP.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
PLBC PLUMAS BANCORP
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ESQ NIKE INC. CLASS B
FGBI ESQUIRE FINANCIAL HOLDINGS
GRX FIRST GUARANTY BANCSHARES
CABA THE GABELLI HEALTHCARE & WELLNESSRX TRUST
JYNT CABALETTA BIO
ALLY THE JOINT
ALT GMAC LLC
APG ALTIMMUNE INC
ZNTL API GROUP CORP
AVO ZENTALIS PHARMACEUTICALS
IVFH MISSION PRODUCE
TMC INNOVATIVE FOOD HLDG
IMRX TMC THE METALS CO INC
LUCY IMMUNEERING CORP
PMCB INNOVATIVE EYEWEAR INC
GLSI PHARMACYTE BIOTECH INC
VANI GREENWICH LIFESCIENCES INC
ACRV VIVANI MEDICAL INC
SUNS ACRIVON THERAPEUTICS INC
GF SUNRISE REALTY TRUST
MSTR THE NEW GERMANY FUND
MPTI INC.
MIGI MICROSTRATEGY INCORPORATED
SQNS M-TRON INDUSTRIES
INC.
MAWSON INFRASTRUCTURE GROUP INC
SEQUANS COMMUNICATIONS
- Jonathan Moreland
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Adva...
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers -Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional target solid tumor and hematologic cancers -Program builds on early clinical evidence of monotherapy activity observed in immune checkpoint inhibitor (CPI)-refractory metastatic melanoma in a previously completed trial CHICAGO and...
- Jonathan Moreland
- Jonathan Moreland
SCL STEPAN COMPANY
MOD MODINE MANUFACTURING COMPANY
LTC LTC PROPERTIES INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
DAKT DAKTRONICS INC.
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
WHF WHITEFIELD
ADC AGREE REALTY CORPORATION
PAR PAR TECHNOLOGY CORP.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
PLBC PLUMAS BANCORP
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ESQ NIKE INC. CLASS B
FGBI ESQUIRE FINANCIAL HOLDINGS
GRX FIRST GUARANTY BANCSHARES
JYNT THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ALT THE JOINT
APG ALTIMMUNE INC
ZNTL API GROUP CORP
IVFH ZENTALIS PHARMACEUTICALS
TMC INNOVATIVE FOOD HLDG
IMRX TMC THE METALS CO INC
WRB IMMUNEERING CORP
LUCY W.R. BERKLEY CORPORATION
PMCB INNOVATIVE EYEWEAR INC
GLSI PHARMACYTE BIOTECH INC
MAIA GREENWICH LIFESCIENCES INC
ACRV MAIA BIOTECHNOLOGY INC
SUNS ACRIVON THERAPEUTICS INC
GF SUNRISE REALTY TRUST
MSTR THE NEW GERMANY FUND
MPTI INC.
SQNS MICROSTRATEGY INCORPORATED
MIGI M-TRON INDUSTRIES
INC.
SEQUANS COMMUNICATIONS
MAWSON INFRASTRUCTURE GROUP INC
- Jonathan Moreland
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomiz...
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib combination reduced the risk of death by 38% compared with gemcitabine/nab-paclitaxel alone, with increased durable survival observed beyond 24 mon...
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milesto...
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximat...
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in...
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 cli...
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 ...
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic neuroblastomaClinical responses and disease control observed in 15 of 40 patients with difficult-to-treat refractory pediatric cancers, including 10 of 19 patients treated with elraglusib plus cyclophosphamide/topotecanData support advancing clinical development of elra...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and we...
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a C...
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at 4:00 p.m. ET on Wednesday, January 7, 2026 to provide an update on 12-month overall survival (OS) from its ongoing Phase 2a clinical trial of atebimetinib + modified G...
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selecte...
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 CHICAGO and FORT WORTH, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3β (GSK-3β), today announced that data from its Phase 2 study evaluating elraglusib in metastatic pancreatic cancer have been selected for an oral pre...
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimeti...
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA – End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks – NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-...
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering’s addition will become effective prior to market open on Monday, December 22, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classifie...
Actuate Therapeutics Announces Publication of Positive Phase II Clinic...
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a historically difficult-to-treat refractory disease CHICAGO and FORT WORTH, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” ...
Terns Announces Closing of Public Offering of Common Stock, Including ...
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per sh...
Terns Announces Pricing of Upsized $650 Million Public Offering
Terns Announces Pricing of Upsized $650 Million Public Offering FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $65...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.